NeurOptic
Therapy for Glaucoma
Health Tech & Life Sciences
Non Active, Apr 2018 ceased to operate
Company Overview
Snapshot
Founded in April 2017, NeurOptic operated with 1–10 employees. The company secured its Seed funding round in November 2017 with investment from Youdim Pharmaceuticals.
Business overview
NeurOptic is a Health Tech & Life Sciences company focused on developing therapies for glaucoma. The company's core product is an ophthalmic formulation based on an FDA-approved drug, designed to provide sustained delivery of a monoamine oxidase inhibitor for two months. NeurOptic serves the pharmaceutical and healthcare markets, specifically targeting eye diseases and ophthalmology.
Log in to access full profile ›Company Intelligence Q&A
- What is NeurOptic's primary focus?
- NeurOptic is focused on developing a novel therapy for glaucoma, utilizing an ophthalmic formulation based on an FDA-approved drug.
- When was NeurOptic founded?
- NeurOptic was founded in April 2017.
- What is the status of NeurOptic?
- NeurOptic is currently non-active and ceased to operate in April 2018.
- Which investor participated in NeurOptic's Seed funding round?
- In November 2017, Youdim Pharmaceuticals invested in NeurOptic's Seed funding round.
- What is the core technology behind NeurOptic's product?
- NeurOptic's lead product for glaucoma is based on a monoamine oxidase inhibitor, formulated for prolonged residence time on the ocular surface to provide sustained drug delivery.